South Korea’s Fair Trade Commission (FTC) will investigate e-commerce giant Coupang Inc. for suspicion of forcing employees to post false reviews on private brand (PB) products to attract customers, industry.
Civic groups had filed reports with the antitrust regulator about the suspected act by Coupang and its subsidiary CPLB.
While cases reported to the FTC are usually dealt with by regional offices, Coupang’s case will be handled by its headquarters due to the potential social impact.
Civic groups claimed in a press conference that Coupang mobilized employees without any proper compensation to write false reviews since last July.
Coupang supposedly wanted to bring more exposure to its private brand products.
The FTC is also investigating Coupang for manipulating algorithms to prioritize Coupang’s PB products on the top of its rankings since June.


Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Singapore Budget 2026 Set for Fiscal Prudence as Growth Remains Resilient
Silver Prices Plunge in Asian Trade as Dollar Strength Triggers Fresh Precious Metals Sell-Off
Federal Judge Rules Trump Administration Unlawfully Halted EV Charger Funding
California Sues Trump Administration Over Federal Authority on Sable Offshore Pipelines
Thailand Inflation Remains Negative for 10th Straight Month in January
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Meta Faces Lawsuit Over Alleged Approval of AI Chatbots Allowing Sexual Interactions With Minors
Federal Judge Signals Possible Dismissal of xAI Lawsuit Against OpenAI
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
U.S. Stock Futures Slide as Tech Rout Deepens on Amazon Capex Shock 



